Pfizer remains “confident in the years ahead,” CEO Albert Bourla said, pointing to investments in oncology, obesity and migraine to power the company’s next phase of growth. New York-headquartered Pfizer is working to offset an estimated $18 billion loss of revenue from patent expirations of household brands such as Lipitor (atorvastatin) between 2026 and 2028, as well as weakened demand for COVID-19-related products such as Paxlovid (nirmatrelvir tablets; ritonavir tablets) since the pandemic.